SCHEMBL8427664

SCHEMBL8427664

CCNC(=O)C(CC1CC1)[C@H](CCC1CC1)C(N)=O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
REN P00797 1/20 0.33
CYP2C9 P11712 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33
METAP2 P50579 2/20 0.32
ALDH1A1 P00352 2/20 0.32
MAPK1 P28482 1/20 0.32
CTSS P25774 1/20 0.32
CTSK P43235 1/20 0.32
CPB2 Q96IY4 2/20 0.31
ABL1 P00519 1/20 0.31
FGFR3 P22607 1/20 0.31
DDR1 Q08345 1/20 0.31
MAPK11 Q15759 1/20 0.31
MAPK14 Q16539 1/20 0.31
DDR2 Q16832 1/20 0.31
MAP3K20 Q9NYL2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14348564 1.00 ACACB (0.33) ACACBTDP1RENCYP2C9CYP1A2
SCHEMBL14348285 0.96 METAP2 (0.38) RENMETAP2ALDH1A1CTSSCTSK
SCHEMBL13359678 0.96 METAP2 (0.38) RENMETAP2ALDH1A1CTSSCTSK
SCHEMBL8427666 0.96 METAP2 (0.38) RENMETAP2ALDH1A1CTSSCTSK
SCHEMBL14348134 0.96 METAP2 (0.38) RENMETAP2ALDH1A1CTSSCTSK
SCHEMBL14348288 0.96 METAP2 (0.35) ACACBRENMETAP2ALDH1A1MAPK1
SCHEMBL8426458 0.96 METAP2 (0.35) ACACBRENMETAP2ALDH1A1MAPK1
SCHEMBL14348289 0.94 METAP2 (0.38) RENMETAP2ALDH1A1CPB2ABL1
SCHEMBL13359716 0.94 METAP2 (0.38) RENMETAP2ALDH1A1CPB2ABL1
SCHEMBL14374472 0.93 METAP2 (0.38) RENMETAP2ALDH1A1CTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718795-B2 Succinoylamino benzodiazepines as inhibitors of aβ protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2010-05-18 US disclosed
US-7507815-B2 Succinoylamino lactams as inhibitors of a-β protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2009-03-24 US disclosed
US-20090069293-A1 SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2009-03-12 US disclosed
US-20080293692-A1 SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-11-27 US disclosed
US-7456172-B2 Succinoylamino benzodiazepines as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-11-25 US disclosed
US-20080207602-A1 SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF ABETA PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-08-28 US disclosed
US-20060122169-A1 Succinoylamino benzodiazepines as inhibitors of Abeta protein production DUPONT PHARMACEUTICALS (US) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069293-A1 SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION GABRA5, APP, GABRE ACACB 629/4885TDP1 3380/4885REN 2937/4885
US-20080293692-A1 SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION BACE1, APH1A, APP ACACB 204/4885TDP1 2065/4885REN 2625/4885
US-20080207602-A1 SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF ABETA PROTEIN PRODUCTION BACE1, APP, GABRE ACACB 974/4885TDP1 2425/4885REN 3586/4885
US-20060122169-A1 Succinoylamino benzodiazepines as inhibitors of Abeta protein production BACE1, APP, GABRE ACACB 974/4885TDP1 2425/4885REN 3586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.